Acute and short-term administrations of delta-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6 mice

[1]  Ruth Ann Marrie,et al.  The prevalence of MS in the United States , 2019, Neurology.

[2]  A. Torres-Suárez,et al.  Medical Use of Cannabinoids , 2018, Drugs.

[3]  J. Zweier,et al.  A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. , 2018, Cell metabolism.

[4]  Pankaj Gupta,et al.  The analgesic potential of cannabinoids. , 2018, Journal of opioid management.

[5]  David S. Wishart,et al.  HMDB 4.0: the human metabolome database for 2018 , 2017, Nucleic Acids Res..

[6]  B. Kong,et al.  Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance , 2017, PloS one.

[7]  D. Butterfield,et al.  Oxidative stress and neurodegeneration , 2017, Brain Research Bulletin.

[8]  Y. Kitagishi,et al.  PI3K/AKT signaling mediated by G protein‑coupled receptors is involved in neurodegenerative Parkinson's disease (Review). , 2017, International journal of molecular medicine.

[9]  H. Hayashi,et al.  Involvement of GSK-3β Phosphorylation Through PI3-K/Akt in Cerebral Ischemia-Induced Neurogenesis in Rats , 2016, Molecular Neurobiology.

[10]  Inês Barroso,et al.  Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis , 2016, PLoS medicine.

[11]  G. Marsicano,et al.  Cannabinoid CB1 Receptors Are Localized in Striated Muscle Mitochondria and Regulate Mitochondrial Respiration , 2016, Front. Physiol..

[12]  G. Werstuck,et al.  Comprehensive Plasma Metabolomic Analyses of Atherosclerotic Progression Reveal Alterations in Glycerophospholipid and Sphingolipid Metabolism in Apolipoprotein E-deficient Mice , 2016, Scientific Reports.

[13]  R. Aebersold,et al.  NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice , 2016, Science.

[14]  M. Nagarkatti,et al.  RNA-seq Analysis of δ9-Tetrahydrocannabinol-treated T Cells Reveals Altered Gene Expression Profiles That Regulate Immune Response and Cell Proliferation* , 2016, The Journal of Biological Chemistry.

[15]  X. Lai,et al.  Analysis of 2-(2-Phenylethyl)chromones by UPLC-ESI-QTOF-MS and Multivariate Statistical Methods in Wild and Cultivated Agarwood , 2016, International journal of molecular sciences.

[16]  Monica Chagoyen,et al.  MBROLE 2.0—functional enrichment of chemical compounds , 2016, Nucleic Acids Res..

[17]  M. Nagarkatti,et al.  Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation , 2016, Journal of Molecular Medicine.

[18]  M. Nagarkatti,et al.  Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation , 2016, Journal of Molecular Medicine.

[19]  Anastasia L. Sowers,et al.  Mass Spectrometry-Based Metabolomics Identifies Longitudinal Urinary Metabolite Profiles Predictive of Radiation-Induced Cancer. , 2016, Cancer research.

[20]  Fang Wu,et al.  Metabolomic study of corticosterone-induced cytotoxicity in PC12 cells by ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry. , 2016, Molecular bioSystems.

[21]  E. J. Wagner.  Sex differences in cannabinoid-regulated biology: A focus on energy homeostasis , 2016, Frontiers in Neuroendocrinology.

[22]  F. Pavón,et al.  Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle , 2015, PloS one.

[23]  E. Verdin.  NAD+ in aging, metabolism, and neurodegeneration , 2015, Science.

[24]  M. Nagarkatti,et al.  Δ9‐Tetrahydrocannabinol attenuates allogeneic host‐versus‐graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid‐derived suppressor cells , 2015, Journal of leukocyte biology.

[25]  K. Hill.  Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. , 2015, JAMA.

[26]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[27]  M. Nagarkatti,et al.  Δ9‐Tetrahydrocannabinol‐mediated epigenetic modifications elicit myeloid‐derived suppressor cell activation via STAT3/S100A8 , 2015, Journal of leukocyte biology.

[28]  J. Bussink,et al.  Improving chemoradiation efficacy by PI3-K/AKT inhibition. , 2014, Cancer treatment reviews.

[29]  J. Bronstein,et al.  Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders , 2014, Neurology.

[30]  G. Kaplan,et al.  Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease , 2014, Inflammatory bowel diseases.

[31]  J. Wiley,et al.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model , 2014, Pharmacology Biochemistry and Behavior.

[32]  J. Korzenik,et al.  Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[33]  R. Pearson,et al.  AKT-independent PI3-K signaling in cancer – emerging role for SGK3 , 2013, Cancer management and research.

[34]  K. Franson,et al.  The Pharmacologic and Clinical Effects of Medical Cannabis , 2013, Pharmacotherapy.

[35]  E. Benarroch.  Endogenous opioid systems , 2012, Neurology.

[36]  Z. Cai,et al.  Metabolite profiling of plasma and urine from rats with TNBS‐induced acute colitis using UPLC‐ESI‐QTOF‐MS‐based metabonomics – a pilot study , 2012, The FEBS journal.

[37]  J. Mehta,et al.  Cannabinoids and Atherosclerotic Coronary Heart Disease , 2012, Clinical cardiology.

[38]  C. Aiello,et al.  Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. , 2012, Current drug abuse reviews.

[39]  M. Silverberg,et al.  Cannabis use amongst patients with inflammatory bowel disease , 2011, European journal of gastroenterology & hepatology.

[40]  I. K. Jordan,et al.  A method for visualization of “omic” datasets for sphingolipid metabolism to predict potentially interesting differences[S] , 2011, Journal of Lipid Research.

[41]  J. Zajicek,et al.  Role of Cannabinoids in Multiple Sclerosis , 2011, CNS Drugs.

[42]  Monica Chagoyen,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[43]  Mahmoud A. ElSohly,et al.  Potency Trends of Δ9‐THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008 * , 2010, Journal of forensic sciences.

[44]  Hong Zhang,et al.  Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis , 2009, Inflammatory bowel diseases.

[45]  M. Nagarkatti,et al.  Cannabinoids as novel anti-inflammatory drugs. , 2009, Future medicinal chemistry.

[46]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[47]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[48]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  B. Costa.  On the Pharmacological Properties of Δ9‐Tetrahydrocannabinol (THC) , 2007 .

[50]  L. Horrocks,et al.  Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide , 2007, Journal of neuroscience research.

[51]  M. Owen,et al.  Association analysis of AKT1 and schizophrenia in a UK case control sample , 2007, Schizophrenia Research.

[52]  E. Doménech,et al.  Utilización de medicinas alternativas y consumo de drogas por pacientes con enfermedad inflamatoria intestinal , 2007 .

[53]  A. Dubin,et al.  Emerging medicinal roles for lysophospholipid signaling. , 2006, Trends in molecular medicine.

[54]  M. Zeira,et al.  Cannabidiol lowers incidence of diabetes in non-obese diabetic mice , 2006, Autoimmunity.

[55]  S. Ward,et al.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. , 2005, Gastroenterology.

[56]  George Perry,et al.  Oxidative Stress and Neurodegeneration , 2005, Annals of the New York Academy of Sciences.

[57]  C. Stadelmann,et al.  Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis , 2004, Cell Death and Differentiation.

[58]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[59]  Benjamin J. Whalley,et al.  Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects? , 2003 .

[60]  D. Walsh,et al.  Established and potential therapeutic applications of cannabinoids in oncology , 2003, Supportive Care in Cancer.

[61]  M. Nagarkatti,et al.  Δ9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo , 2002, Journal of Pharmacology and Experimental Therapeutics.

[62]  H. Turndorf,et al.  A molecular basis of the therapeutic and psychoactive properties of cannabis (Δ9-tetrahydrocannabinol) , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[63]  Jean-François Trottier,et al.  Role of endogenous opioid system in the regulation of the stress response , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[64]  H. Fields,et al.  Pain modulation: expectation, opioid analgesia and virtual pain. , 2000, Progress in brain research.

[65]  J B Schulz,et al.  Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.

[66]  K. Gibson,et al.  Tiglylglycine excreted in urine in disorders of isoleucine metabolism and the respiratory chain measured by stable isotope dilution GC-MS. , 1994, Clinical chemistry.

[67]  I. Yamamoto,et al.  Sex difference in hepatic microsomal aldehyde oxygenase activity in different strains of mice. , 1992, Research communications in chemical pathology and pharmacology.

[68]  D. Carr.  The Role of Endogenous Opioids and Their Receptors in the Immune System , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[69]  W. Kromer.  Endogenous opioids, the enteric nervous system and gut motility. , 1990, Digestive diseases.

[70]  S. Pinder,et al.  The pathway of biosynthesis of nicotinamide-adenine dinucleotide in rat mammary gland. , 1968, The Biochemical journal.

[71]  Xian-cheng Jiang,et al.  Sphingolipid metabolism and atherosclerosis. , 2013, Handbook of experimental pharmacology.

[72]  J. Kowalski.  Cannabis therapy. , 2013, Deutsches Arzteblatt international.

[73]  W. Feneberg,et al.  Current Management of Pain Associated with Multiple Sclerosis , 2008, CNS drugs.

[74]  B. Costa.  On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). , 2007, Chemistry & biodiversity.

[75]  M. Gassull,et al.  [Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease]. , 2007, Medicina clinica.

[76]  M. Parsons,et al.  Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. , 2003, European journal of pharmacology.

[77]  Benjamin J. Whalley,et al.  Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? , 2003, The Journal of pharmacy and pharmacology.

[78]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[79]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[80]  M. Durán,et al.  The identification of (E)-2-methylglutaconic acid, a new isoleucine metabolite, in the urine of patients with beta-ketothiolase deficiency, propionic acidaemia and methylmalonic acidaemia. , 1982, Biomedical mass spectrometry.